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Abstract 
Background: Cisplatin causes male infertility but the exact mechanism have not been clarified, yet. MOTILIPERM has 
been implicated in alleviation of infertility in Sprague–Dawley rats caused by cisplatin. We evaluated recovery effect of 
MOTILIPERM on cisplatin (CIS)-induced testicular toxicity in Sprague–Dawley rats.
Methods: Five groups were included. The groups are control (CTR), CTR + MOTILIPERM 200 mg/kg/day per oral, CIS 
10 mg/kg i.v., CIS 10 mg/kg + MOTILIPERM 100 mg/kg/day, CIS 10 mg/kg + MOTILIPERM 200 mg/kg/day. CIS 10 mg/
kg i.v. single dose was given before 100 mg/kg, or 200 mg/kg MOTILIPERM per oral daily for 28 days. Body and genital 
organs weight, epididymis sperm count, sperm motility, sperm apoptosis, testosterone level, MDA of testis tissue, 
spermatogenic cell density, and Johnsen’s score were evaluated. Steroidogenic acute regulatory (StAR) protein, and 
Glucose-regulated protein-78 (GRP-78), phosphorylated Inositol-Requiring Transmembrane Kinase/Endoribonuclease 
1 (IRE1) and phosphorylated c-jun-N-terminal kinase (p-JNK) were quantitated by western blot to show its signaling 
pathway.
Results: The body weight was decreased significantly in CIS 10 mg/kg, CIS 10 mg/kg + MOTILIPERM 100 mg/kg/day, 
CIS 10 mg/kg + MOTILIPERM 200 mg/kg/day compared with CTR (p < 0.001) however, it was increased in CIS 10 mg/
kg + MOTILIPERM 100 mg/kg/day, CIS 10 mg/kg + MOTILIPERM 200 mg/kg/day compared with CIS 10 mg/kg. The 
decreased weight of epididymis and prostate were increased significantly in CIS 10 mg/kg + MOTILIPERM 100 mg/kg/
day compared with CIS 10 mg/kg. Sperm count, sperm motility, sperm apoptosis, MDA of testis tissue, spermatogenic 
cell density, Johnsen’s score, and total testosterone were also significantly improved by MOTILIPERM treatment. The 
levels of decreased StAR protein was significantly improved by MOTILIPERM administration, increased GRP-78 protein 
p-IRE1and p-JNK was also significantly decreased with MOTILIPREM treatment.
Conclusion: The MOTILIPERM could be an effective medicine to reduce the toxic effect caused ER stress by CIS in the 
testis.
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Background
Cis-diamminedichloroplatinum (II) (cisplatin or cisplati-
num, CIS), an antineoplastic drug made in the end of 
the 19th century, around the peculiar atomic configura-
tion of platinum and was described by the Italian chemist 
Michele Peyrone [1, 2]. CIS has been used worldwide for 
treatment of other solid neoplasms, including head and 
neck, lung, colorectal, hematologic, and ovarian cancers 
[3, 5]. In 1978 the US Food and Drug Administration 
(FDA) approved the use of CIS for use in testicular and 
bladder cancer patients [4].
Effects of CIS treatment on testicular function have 
been noted in human [6] and other animal models [7, 
8]. Animals administered CIS develop severe testicular 
damage characterized by germ cell apoptosis, Leydig cell 
dysfunction and testicular steroidogenic disorder leading 
to infertility. Spermatogenesis is affected by CIS by inhib-
iting nucleic acid synthesis of germ cells [10]. CIS also 
inhibit testosterone production by damage of Leydig cells 
[11].
CIS forms covalent adduct with the cellular DNA mol-
ecules and terminate the vital processes like replication 
and transcription and induce apoptosis [12]. The molecu-
lar mechanism by which CIS causes reproductive toxicity 
and germ-cell apoptosis remains to be elucidated [13, 14].
Alternative methods therefore different herbal medi-
cines like Zingiber officinale and Hibiscus sabdariffa, 
Curcuma longa, Ginkgo biloba or other agents like mel-
atonin, amifostine are used to improve the infertility 
caused by CIS [8, 14, 25, 27, 30].
Cuscuta chinensis, a Chinese Dodder is a parasitic 
plant. It is commonly used in traditional medicine. It is 
often used to improve sexual potency [16]. Total fla-
vones from Cuscuta chinensis seeds can increase the 
testosterone level in the testicle [17]. Allium cepa has 
antioxidative and androgenic effects in rats that promote 
spermatogenesis cycle [19, 21, 22]. Morinda officinalis is 
also used to improve the sperm motility [18]. Usually one 
or the mixture of two herbal medicines are used to treat 
the testicular toxicity, but we have selected three differ-
ent herbal medicines to improve the male fertility who 
are treated with CIS. We used this mixture of three to 
clarify whether they can improve the CIS inducing male 
infertility.
Methods
Animals, chemicals, experiment protocol
The study was approved by the Ethical Committee of 
Chonbuk National University followed Basel Declara-
tion. Sexually mature male SD rats weighing 250–300 
gm and 9–10 weeks of age were used. The rats were ran-
domly divided into five groups containing 10 rats each, 
except for the control group with 6 rats. The rats were 
fed standard rat chow prepared by Feedlab (Guri, Gyeo-
nggi, South Korea) and had access to water. They were 
maintained in the animal facility under constant environ-
mental conditions (room temperature 20 ± 2 °C, relative 
humidity 50 ± 10 %, and 12-hour light–dark cycle).
CIS was purchased from Wako Pure Chemical Indus-
tries, Ltd. (Doshomachi, Osaka, Japan). The five groups 
were control (CTR) group (n = 6), CTR + MOTILIPERM 
200 mg/kg per oral (p.o.) (CTR + M 200) group (n = 9), 
CIS 10  mg/kg intravenous (i.v.) (CIS) group (n  =  8), 
CIS 10  mg/kg i.v. +  MOTILIPERM 100  mg/kg/day p.o. 
group (CIS + M 100) group (n = 10), and CIS 10 mg/kg 
i.v. + MOTILIPERM 200 mg/kg/day p.o. (CIS + M 200) 
group (n = 7). The remaining rats died as we had taken 
10 rats in each group, except the control group. All rats 
were sacrificed after 28 days. CIS 10 mg/kg body weight 
mixed in normal saline was given i.v. by the tail vein; this 
group was sacrificed 7 days after the CIS injection, since 
we have previously demonstrated the high mortality of 
rats treated with CIS for more than 7 days. The recovery 
group that received the CIS was given MOTILIPERM 
(100 or/and 200) mg/kg/day p.o. for 28  days beginning 
the day following CIS administration. Doses of MOTILI-
PERM were selected based on previous experiments in 
our laboratory. We used a 28-day MOTILIPERM treat-
ment period because the normal spermatogenesis period 
of rats is 12.9 days [9].
Plant material
MOTILIPERM is currently under development by the 
Dong-A Pharmaceutical Company (Kyoungi, South 
Korea) for the treatment of infertility. It was mixed in 
normal saline. It included Morinda officinalis, Cuscuta 
chinensis and Allium cepa (100 or 200  mg/kg/day) was 
given orally for 28 days.
Extraction and fractionation of MOTILIPERM
MOTILIPERM was prepared the mixtures of three 
medicinal herbs. Each herb was ground and extracted 
three times with ethanol under reflux for 3 h at 70–80 °C. 
The combined filtrate was concentrated by rotary evap-
orator and freeze dried, and stored at −20  °C until 
required. The quality of MOTILIPERM was confirmed 
by its principal constituents using high-performance 
liquid chromatography (HPLC). Twenty milligrams of 
MOTILIPERM was dissolved in 30 mLmethanol and fil-
tered through a 0.45  μM membrane filter. Ten microlit-
ers of the filtrate was injected into the HPLC system for 
analysis. Each peak of MOTILIPERM in the HPLC pro-
file was identified by comparison with the retention times 
and UV spectra of standard compounds. An Agilent 1200 
HPLC system with an INNO column C18 (4.6 × 250 mm, 
YoungJin Biochrom, Seoul, South Korea) was used at a 
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flow-rate of 1.0 mL/min at 40 °C. The mobile phase con-
sisted of acetonitrile containing 0.1 % trifluoroacetic acid 
(solvent A) and water containing 0.1 % trifluoroacetic acid 
(solvent B). A linear gradient system consisted of 0–0 % 
A for 0–10 min, 0–30 % A for 10–40 min, 30–50 % A for 
40–50 min, 50–100 % A for 50–60 min and 100 % A for 
60–70 min. The chromatographic profile of the effluents 
was recorded at 240 and 254 nm with a spectrum ranging 
from 210 to 450 nm. The HPLC profile of MOTILIPERM 
and its identified compounds are shown in Fig. 1.
Samples collection
The rats were sacrificed using a mixture of Ketamin 
(100 mg/mL) and 2 % rumpun (20 mg/mL).
Sperm count and motility
The epididymis was minced and suspended in normal 
saline at 37  °C for 5  min. The sperm suspension was 
placed on a sperm-counting chamber (SEFI-Medical 
Instruments, Haifa, Israel) with a pipettor. The chamber 
was warmed to 37  °C before sperm counts and motil-
ity were assessed. The total sperm count was calculated 
using two or three drops of the specimen to increase the 
reliability of count determination. Sperm heads were 
counted in 10 squares. The recorded sperm count rep-
resents the concentration of sperm as millions of sperm 
per ml. The average value was reported. The sperm were 
counted using the 20 X magnification objective on the 
light microscope.
Sperm apoptosis
The number of apoptotic sperms was analyzed by flow 
cytometry using a Gallios™ device (Beckman Coulter, 
Brea, CA, USA). Propidium iodide was purchased from 
BD Pharmigen (San Diego, CA, USA). Five microlitre of 
semen sample was taken in an Eppendorf tube, 100 µL 
binding buffer was added, 5 µL propidium iodide was 
added, and the mixture was incubated at room tem-
perature in dark for 20 min. Binding buffer (400 µL) was 
added and apoptosis was measured within an hour.
Biochemistry
Blood was collected from rats’ vena cava. For testoster-
one estimation, 10 µL heparin was added in 1 mL blood 
and was centrifuged at 3500g for 10  min. Plasma was 
transferred to a 5  mL tube and sealed with the paraffin 
film. All the samples were sent to the hospital laboratory.
Malondialdehyde (MDA)
Malondialdehyde is a marker for oxidative stress. 
Homogenized testis tissue was used for MDA analysis. 
MDA analysis is based on its reaction with thiobarbituric 
acid to form a pink complex with absorption maximum 
at 535 nm [13].
Histology
For histological estimations, small pieces of testis were 
fixed in the formalin and stained with hematoxylin and 
eosin. Sections were examined by light microscopy for 
spermatogenic cell density measurements. Spermato-
genic cell density was determined by measuring the 
thickness of the germinal cell layer and the diameter of 
the seminiferous tubules.
Seminiferous tubules were graded by Johnsen’s scoring. 
In this system of classification, seminiferous tubules are 
assessed according to the presence of spermatogenic cells 
and each is given a score from 1 to 10. Complete sper-
matogenesis with many spermatozoa present is evalu-
ated as score 10. The detailed score histological criteria 
[28] are: Score 1: No seminiferous epithelium; Score 2: 
No germinal cells, Sertoli cells only; Score 3: Spermato-
gonia only; Score 4: No spermatozoa or spermatids, few 
spermatocytes; Score 5: No spermatozoa or spermatids, 
many spermatocytes; Score 6: No spermatozoa, no late 
spermatids, few early spermatids; Score 7: No sperma-
tozoa, no late spermatids, many early spermatids; Score 
8: Less than five spermatozoa per tubule, few late sper-
matids; Score 9: Slightly impaired spermatogenesis, many 
late spermatids, disorganized epithelium.; and Score 10: 
Full spermatogenesis.
Western blot
Glucose-regulated protein-78 (GRP-78), phosphorylated 
Inositol-Requiring Transmembrane Kinase/Endoribo-
nuclease 1 (IRE1), total IRE1, phosphorylated c-jun-N-
terminal kinase (p-JNK) and total JNK measurements in 
testis tissue were conducted with obtained tissue that had 
been washed with cold phosphate buffered saline (PBS). 
Lysis buffer with protease inhibitor was added to tissue, 
cordless motor pellet pestles was used to pestle and cen-
trifuge at 12,000 rpm for 30 min at 4 °C.
For StAR protein, crude mitochondrial preparation 
was acquired as previously described [29]. Testis tis-
sue was thoroughly washed in 2  mL of sucrose buffer 
(0.25 M sucrose, 10 mM tris, 0.1 mM EDTA and pH 7.4) 
and the homogenate centrifuged at 600 rpm for 15 min. 
The cloudy supernatant, containing the mitochondria 
was removed and transferred to another tube which was 
then centrifuged at 12,000  rpm for 15  min. The result-
ing mitochondrial pellet was washed in sucrose buffer 
and recentrifuged at 12,000  rpm for 15  min. The pellet 
was again re-suspended in sucrose buffer and the protein 
content determined by the method of Bradford for both 
the lysates.
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The samples were run on 10 % sodium dodecyl sulfate 
(SDS) gel, transferred on polyvinylidene fluoride (PVDF) 
membrane by trans-blot® SD semi-dry electrophoretic 
transfer cell (Bio-Rad, Hercules, CA, USA). After trans-
fer, the membrane was blocked by 10  % Bovine serum 
albumin (BSA) for an hour and incubated with phospho-
rylated antibodies p-IRE1(Abcam Cambridge, MA USA), 
p-JNK (Santa Cruz Biotechnology, Dallas, TX, USA) but 
non-fat 10 % milk was used for non-phosphorylated anti-
bodies GRP-78, IRE1, and JNK (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) for testis tissue. StAR protein (Cell 
Signaling Technology, Beverly, MA, USA) for mitochon-
drial extracts with a 1:1000 dilution overnight at 4  °C. 
The membrane was washed with Tris buffered saline 
Tween (TBST) three times prior to the addition of 1:5000 
dilution of secondary antibody for 1  h. The membrane 
was washed three times with TBST and processed using 
enhanced chemiluminescence substrate.
Statistical analysis
Data are expressed as mean ± SD. The statistical analy-
sis was carried out using SigmaPlot 12.0 (Systat Software, 
San Jose, CA, USA). P < 0.001 was considered statistically 
significant.
Results
Effect of weights of body, testis, epididymis, and prostate
The weights of body in CIS, CIS + M 100, and CIS + M 
200 groups were significantly decreased compared with 
the CTR group. Body weight significantly increased in 
CIS +  M 100, and CIS +  M 200 groups compared with 
CIS group, and in CIS + M 100 compared with CTR + M 
200 group. Testis weight had no statistical significance. 
Epididymis weight in CIS group was significantly decreased 
compared with CTR group, and in CIS + M 100 compared 
with CTR + M 200 and CIS groups. There was a signifi-
cant decrease in prostate weight in CIS, CIS + M 100, and 
CIS +  M 200 groups compared with CTR group, and in 
CIS + M 200 group compared with CIS group (Table 1).
Effect on sperm count
The sperm count in CIS group was significantly 
decreased compared with CTR + M 200 group (Table 2).
Effect on sperm motility
There was significant decrease sperm motility in CIS, 
CIS + M 100, and CIS + M 200 groups compared with 
CTR group, and in CIS + M 100 group compared with 
CTR + M 200 group (Table 2).
Effect on sperm apoptosis
There was significant increase apoptosis in CIS group 
compared with CTR group, and in CIS, CIS  +  M 100, 
and CIS + M 200 groups compared with CTR + M 200 
group. There was significantly decreased apoptosis in 
CIS + M 100 and CIS + M 200 groups compared with 
CIS group (Table 2).
Effect on MDA
There was significant increase in MDA level in CIS, 
CIS + M 100 and CIS + M 200 groups compared with 
CTR and CTR + M 200 groups. There was also signifi-
cant decrease of MDA level in CIS + M 100 and CIS + M 
200 group compared with CIS group (Fig. 2).
(See figure on previous page.) 
Fig. 1 HPLC chromatogram of MOTILIPERM and ultraviolet spectra of major marker components from each herbal ingredients. Monotropein (1) 
and deacetyl asperulosidic acid (2) from the Morinda officinalis; Chlorogenic acid (3) and 3,5-dicaffeoylquinic acid (4) from the Cuscuta japonica; 
quercetin 4′-glcoside (5) and quercetin (6) from the Allium cepa. Each peak of MOTILIPERM in the HPLC chromatogram was identified by comparison 
with the retention times and UV spectra of standard compounds
Table 1 The effect of the MOTILIPERM on body, testicular, epididymis and prostate weights
Data are presented in mean ± SD
Wt weight; CTR control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 
100 mg/kg/day; CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day. M MOTILIPERM
*   p < 0.05 vs CTR group, † p < 0.05 vs CTR + M 200 group, # p < 0.05 vs CIS group, ** p < 0.001 vs CTR group, †† p < 0.001 vs CTR M 200 group 2, ## p < 0.001 vs CIS 
group
CTR CTR + M 200 CIS groups
CIS CIS + M 100 CIS + M 200
Body Wt (gm) 419 ± 37.22 349.6 ± 13.79 338 ± 16.19** 386.3 ± 16.15*,††,## 358.43 ± 17.82*,#
Testis Wt (gm) 2.05 ± 0.13 1.99 ± 0.10 1.95 ± .014 1.97 ± 0.13 1.96 ± .014
Epididymis Wt (gm) 0.70 ± 0.02 0.60 ± 0.05 0.59 ± 0.05** 0.66 ± 0.05†,# 0.65 ± 0.06
Prostate Wt (gm) 1.48 ± 0.23 1.14 ± 0.18 1.18 ± 0.19* 1.1 ± 0.15* 0.97 ± 0.16**,#
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Effect on plasma testosterone and StAR protein
There was a significant decrease of testosterone level in 
CIS, CIS + M 100, and CIS + M 200 groups compared 
with CTR +  M 200 group (Fig.  3a; Table  3). There was 
significant increase of testosterone in CIS + M 100 group 
compared with CIS group. Significantly decreased StAR 
protein level was evident in CIS group compared with 
CTR and CTR +  M 200 groups. There were no signifi-
cant changes in CIS + M 100 and CIS + M 200 groups 
compared with CIS group (Fig. 3b, c).
Histopathological effects
Testis tissue showed normal arrangement of the germi-
nal cells, Sertoli cells, and Leydig cells without histo-
pathological lesions in CTR and CTR +  M 200 groups. 
Table 2 The effect of the MOTILIPERM on epididymis sperm count, motility and apoptosis
Data are presented in mean ± SD
CTR control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 100 mg/kg/day; 
CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day. M MOTILIPERM
*   p < 0.05 vs CTR group, † p < 0.05 vs CTR + M 200 group 2, # p < 0.05 vs CIS group, †† p < 0.001 vs CTR + M 200 group
CTR CTR + M 200 CIS groups
CIS CIS + M 100 CIS + M 200
Sperm count (106) 25.17 ± 5.95 28.83 ± 6.10 22.06 ± 8.78† 25.40 ± 4.65 28.21 ± 4.46
Sperm motility (%) 33.29 ± 19.01 29.13 ± 15.83 17.56 ± 15.16* 17.87 ± 8.47*,† 19.86 ± 12.91*
Sperm apoptosis (%) 17.38 ± 1.85 8.03 ± 2.96 24.68 ± 4.22*,†† 19.97 ± 4.68††,# 19.90 ± 3.56††,#
Fig. 2 Evaluation of MDA for each group. Data are presented in 
mean ± SD. †p < 0.05 vs CTR + M 200 group, #p < 0.05 vs CIS group, 
**p < 0.001 vs CTR group, ††p < 0.001 vs CTR + M 200 group
Fig. 3 Effects of cisplatin (CIS) and MOTILIPERM on total testosterone and StAR protein by Western blot. a Total testosterone level. b StAR protein. c 
Western blotting of StAR protein for each group. Data are presented in mean ± SD. CTR control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; 
CIS cisplatin 10 mg/kg i intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 100 mg/kg/day; CIS + M 200 CIS 10 mg/kg, i.v. + MOTILI-
PERM 200 mg/kg/day p.o. M MOTILIPERM. *p < 0.05 vs CTR group, †p < 0.05 vs CTR + M 200 group, #p < 0.05 vs CIS group
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CIS group showed degeneration and disorganization of 
germinal cells, Sertoli cells, and Leydig cells. CIS  +  M 
100 and CIS +  M 200 groups showed the degeneration 
and disorganization of the testis tissue, but less than in 
CIS group. There was a significant decrease in the sper-
matogenic cell density in CIS group compared with CTR 
group (Fig.  4a, b; Table  3). Johnsen’s score was signifi-
cantly decreased in CIS and CIS  +  M 100 group com-
pared with CTR and CTR +  M 200 groups, and it also 
was significantly increased in CIS + M 200 group com-
pared with CIS group (Fig. 4c).
GRP‑78, p‑IRE1 and p‑JNK
Significantly increased GRP-78 was evident in CIS and 
CIS  +  M 100 groups compared with CTR  +  M 200 
group. CIS +  M 100 and CIS +  M 200 groups showed 
significantly decreased GRP-78 compared with CIS 
group (Fig.  5a, b). p-IRE1 was significantly increased in 
Table 3 The effect of the MOTILIPERM on testosterone assay and spermatogenic cell density
Data are presented in mean ± SD
CTR control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 100 mg/kg/day; 
CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day
*   p < 0.05 vs CTR group, † p < 0.05 vs CTR + M 200 group, # p < 0.05 vs CIS group
CTR CTR + M 200 CIS groups
CIS CIS + M 100 CIS + M 200
Testosterone (ng/ml) 1.56 ± 1.35 2.74 ± 1.56 0.56 ± 0.78† 1.27 ± 0.95†,# 0.96 ± 1.22†
Spermatogenic cell density 0.35 ± 0.07 0.32 ± 0.08 0.18 ± 0.03* 0.269 ± 0.028 0.26 ± 0.04
Fig. 4 Light microscope evaluations of the testis. a Hematoxylin & Eosin (H&E) staining of the testis. b Spermatogenic cell density. c Johnsen’s score 
in seminiferous tubules. Data are presented in mean ± SD. CTR control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg i 
intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 100 mg/kg/day; CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day p.o. M 
MOTILIPERM. *p < 0.05 vs CTR group, †p < 0.05 vs CTR + M 200 group, #p < 0.05 vs CIS group, **p < 0.001 vs CTR group, ††p < 0.001 vs CTR + M 200 
group
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CIS group compared to CTR and CTR +  M200 groups 
(Fig. 6a, b). Significantly increased p-JNK was evident in 
CIS, CIS + M 100, and CIS + M 200 groups compared 
with CTR group. CIS and group also showed significantly 
increased compared with CTR + M 200 group (Fig. 7a, b).
Discussion
CIS is one of the potent anticancer drugs in the chemo-
therapy treatment; it induces a testicular disintegration, 
sperm dysfunction, germ-cell apoptosis, and abnor-
malities in Leydig cells in rats [7, 23]. CIS has signifi-
cant decrease in the physical weight, reproductive organ 
weights, plasma testosterone level and spermatozoa 
compared with untreated control animals. CIS shows 
impaired fertility along with alterations on the growth 
and development of the next generations [26].
Thus, the toxic effects of CIS on the germ cells led for 
further research either to preserve the fertility in men 
who are undergoing chemotherapy. Semen preservation 
for future use has increased the chances of pregnancies. 
But freezing and thawing of semen can reduce the sperm 
quality [15].
The studies showed the protective effects of herbal 
plants extracts against CIS due to the presence of anti-
oxidant effects in the herbal medicine [24]. Peng et  al. 
studied about the effects of Cuscuta chinensis on human 
sperm motility in vitro function. The results showed that 
the motility of sperm significantly improved and the 
function of sperm membrane became more stable after 
incubation [18]. In young men antioxidants protect DNA 
from oxidation and damage and improve the sperm qual-
ity [20].
Fig. 5 Evaluation of GRP-78. a Western blot of testis. b Levels of GRP-78 for each group. Data are presented in mean ± SD. CTR control; CTR + M 200 
CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg i intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 100 mg/kg/day; CIS + M 
200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day p.o. M MOTILIPERM. †p < 0.05 vs CTR + M 200 group, #p < 0.05 vs CIS group
Fig. 6 Evaluation of p-IRE1, IRE1, a Western blot of testis. b Levels of pIRE1 and total IRE1 for each group. Data are presented in mean ± SD. CTR 
control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg i intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 
100 mg/kg/day; CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day p.o. M MOTILIPERM. *p < 0.005 vs CTR group, †p < 0.05 vs CTR + M 
200 group
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CIS damages testicular tissue and reduces sperm pro-
duction through increasing oxidative stress and inducing 
apoptosis and upregulations of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB), induc-
ible nitric oxide synthase (iNOS), and cyclooxygenase-2 
(COX-2), while Ginkgo biloba reduces these oxidative and 
apoptosis actions of CIS in testis [25]. CIS activate mito-
gen-activated protein kinases (MAPK), nuclear factor-
kappa NF-kB and nitric oxide synthase iNOS expression 
that has role in pathogenesis in rat testis induced by CIS is 
blocked by antioxidant such as Curcuma longa [30].
Zingiber officinale and Hibiscus sabdariffa have also 
been reported to prevent CIS related damage in testicular 
tissue and sperm cells by its antioxidant and anti-inflam-
matory agents [8]. Besides herbal medicines melatonin 
decrease malondialdehyde (MDA) and increase glu-
tathione (GSH) levels in several pathological conditions 
like CIS toxicity [14]. Amifostine partially protect the rat 
seminiferous epithelium against CIS toxicity [27].
There are three signaling pathways from ER Stress 
sensors [31], they are Activating Transcription Factor-6 
(ATF6), Protein kinase RNA-like endoplasmic reticulum 
kinase (PERK) and Inositol-Requiring Transmembrane 
Kinase/Endoribonuclease 1 (IRE1). Prolonged ER stress 
activates IRE1 and it may interacts with tumor necrosis 
factor receptor associated factor 2 (TRAF2) [32]. The 
IRE1-TRAF2 complex may activate (Apoptosis signal-
regulating kinase) ASK1, also known as MAP kinase 
kinase, leading to activation of JNK pathway. ER stress-
induced activation of the ASK1-JNK pathway may trigger 
apoptosis (Fig. 8) [33].
In our study we have designed to show CIS adminis-
tration caused testicular toxicity within a week, which 
recovers by administration of MOTILIPERM orally in 
28  days. MOTILIPERM of different doses offers recov-
ery of apoptotic changes against the CIS. This recovery 
effect was seen in the sperm cell by the flow cytometry 
where apoptosis was more in CIS group than MOTILI-
PERM treated group just after CIS administration. It was 
Fig. 7 Evaluation of pJNK and JNK a Western blot of testis. b Levels of pJNK and total JNK for each group. Data are presented in mean ± SD. CTR 
control; CTR + M 200 CTR + MOTILIPERM 200 mg/kg/day; CIS cisplatin 10 mg/kg i intravenous (i.v.); CIS + M 100 CIS 10 mg/kg, i.v. + MOTILIPERM 
100 mg/kg/day; CIS + M 200 CIS 10 mg/kg, i.v. + MOTILIPERM 200 mg/kg/day p.o. M MOTILIPERM.. *p < 0.05 vs CTR group, †p < 0.05 vs CTR + M 200 
group, **p < 0.001 vs CTR group
Fig. 8 Schematic view of endoplasmic reticulum (ER) stress signaling 
pathway explained. GRP78 Glucose-regulated protein-78 (GRP-78), 
pIRE1 phosphorylated inositol-requiring transmembrane kinase/
endoribonuclease1; IRE1 inositol-requiring transmembrane kinase/
endoribonuclease1; ATF6 activating transcription factor-6; TRAF2 
tumor necrosis factor receptor associated factor2; PERK protein kinase 
RNA-like endoplasmic reticulum kinase; ASK1 apoptosis signal-
regulating kinase; pJNK phosphorylated c-jun-N-terminal kinase; JNK 
c-jun-N-terminal kinase
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further accompanied with the restoration of body weight 
where the testis weight and epididymis weight both were 
restored but in some part, CIS +  M 100 group showed 
better results than the CIS  +  M 200 group. The exact 
mechanism of it is not so clear. Sperm count and sperm 
motility of the epididymis were also seen to increase 
compared to the CIS group. MDA level was increased in 
CIS treated groups.
Total testosterone level was also increased in the recov-
ery group where MOTILIPERM is given just after CIS 
administration. CIS cause damage of the Leydig cells 
[11], so the testosterone production is hampered. The 
StAR protein in the testis tissue showed decreased level 
in CIS group and recovery groups compared with the 
CTR, M-200 group in western blot results.
GRP-78, p-IRE1, and p-JNK proteins were increased in 
CIS, CIS + M 100, and CIS + M 200 groups compared 
with CTR group and CTR  +  M 200 groups but it was 
seen decreased in CIS  +  M 200 group compared with 
other groups. When we see the arrangement of the tes-
tis tissue we also got the decrease of the germ cells den-
sity in the seminiferous tubules in the CIS treated group 
and the group where 200  mg/kg/day of MOTILIPERM 
was given just after the CIS is administered in it, and also 
the disintegration of the Leydig cells that produces the 
testosterone.
Conclusions
This study provides sufficient evidence that CIS has a 
toxic effect on body and reproductive organs by ER stress 
in the rat. MOTILIPERM decreased these detriments, 
and so may be potentially valuable in chemotherapy 
relating infertility.
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